DJO Global is putting the “therapy” in retail therapy: The surgical device maker has now made five acquisitions since last November, with all but one in the reconstructive surgery space.
Medtronic scored FDA approval for its latest spinal cord stimulation implant for chronic pain, with a non-rechargeable device promising nearly double the battery life of previous hardware.
Acumen Pharmaceuticals is filing for a $100 million initial public offering hot on the heels of the FDA’s conditional approval of Biogen’s controversial Alzheimer’s disease drug Aduhelm (aducanumab).
With a new CEO in place and its revenues on the rebound after a tumultuous 2020, Inogen is looking to make its product line of at-home and portable oxygen concentrators bigger and better than ever.
Kurome Therapeutics has raised $15 million to treat acute myeloid leukemia (AML) by targeting adaptive resistance mechanisms. Medicxi and Affinity Asset Advisors co-led the series A round to fund Kurome through IND-enabling studies.
Nearly a year after emerging from a Versant Ventures incubator, Bright Peak Therapeutics is reeling in a $107 million series B. The funding will advance Bright Peak’s pipeline of cytokine medicines toward the clinic and build out its underlying technology, though the company is keeping details close to the vest.
Flagship Pioneering united its “intersystems biology” efforts under one roof last fall, and, now, that company is gearing up for human trials. With a $55 million boost, Senda Biosciences will push three programs into the clinic in 2022, including treatments for chronic kidney disease and metabolic diseases as well as an asset aimed at making checkpoint inhibitors work for more people.
The conditional approval of Biogen’s Aduhelm (aducanumab) might have been controversial, but the FDA’s decision on Monday could spur a renaissance of sorts for the Alzheimer’s space after a “decade of a big hole.”
Though osteoarthritis of the knee is estimated to affect at least 14 million people in the U.S. alone, treatments for the degenerative joint disease remain woefully limited.
A class of antidepressants known as monoamine oxidase inhibitors (MAOIs) first hit the market in the 1950s and has since been eclipsed by drugs that are less likely to cause unwanted side effects. Now, scientists at the University of California, Los Angeles (UCLA) have evidence that these drugs may be able to be repurposed in the treatment of cancer.